Evaluation of a pharmacist-led medication management service
Official title: Primary Care Community Pharmacy Project: Evaluation of Medication Management Service
Run by The University of Hong Kong · NCT06273761 · Data updated 2026-11-12
This study is testing whether a pharmacist-led service can help people with Type 2 diabetes and high blood pressure use their medications better and improve their overall health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 640 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 8 sites (Hong Kong and 7 other locations) |
| Status | Recruiting |
| Started | February 6, 2024 |
| Main results expected | August 1, 2026 |
| Study ends | May 1, 2027 |
| Registry record updated | February 23, 2024 |
| Trial ID | NCT06273761 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and above diagnosed with Type 2 diabetes mellitus and/or hypertension who are taking multiple chronic medications.
✕Probably not a fit
Patients who are not fluent in Cantonese or English, or those unable to provide informed consent, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates a pharmacist-led Medication Management Service (MMS) aimed at optimizing medication use and improving health outcomes for patients with Type 2 diabetes mellitus and hypertension in community pharmacies across Hong Kong. The study involves a randomized controlled design where participants will receive MMS after a control period without the service. The trial will assess patient satisfaction, medication adherence, health-related quality of life, and overall health outcomes. A total of 640 participants will be recruited, and their clinical data will be analyzed to determine the effectiveness and cost-effectiveness of the MMS.
Why it matters
Potential benefit: If successful, this service could significantly enhance medication adherence and health outcomes for patients with chronic conditions.
How similar studies have gone: Other studies have shown positive outcomes with similar pharmacist-led medication management approaches, indicating potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged 18 years or above * diagnosed with Type 2 diabetes mellitus and/or hypertension * having regular follow-up on Type 2 diabetes mellitus and/or hypertension at Hospital Authority * no A\&E admission/hospitalization in the past 3 months * no recent changes in medication regimen in the past 3 months * polypharmacy (taking 5 or more chronic medications) * using at least 1 high-risk medication (Anticoagulants, Oral hypoglycaemics, Insulins, psychotropic medications or immunosuppressants) * able to communicate in Cantonese and/or English Exclusion Criteria: * aged below 18 * unable to give informed consent * unable to communicate in Cantonese and/or English
Where it's running
-
Aberdeen Kai-Fong Welfare Association A-Lively Community Pharmacy
Hong Kong, Hong Kong Recruiting -
Health In Action Community Pharmacy
Hong Kong, Hong Kong Recruiting -
Hong Kong Sheng Kung Hui Welfare Council Community Pharmacy
Hong Kong, Hong Kong Recruiting -
PHARM+ Haven of Hope Community Pharmacy
Hong Kong, Hong Kong Recruiting -
PHARM+ Pok Oi Hospital Community Pharmacy
Hong Kong, Hong Kong Recruiting -
PHARM+ St. James' Settlement Community Pharmacy
Hong Kong, Hong Kong Recruiting
Show 2 more locations
-
PHARM+ The Lok Sin Tong Community Pharmacy
Hong Kong, Hong Kong Recruiting -
PHARM+ YWCA Community Pharmacy
Hong Kong, Hong Kong Recruiting
Study contacts
- Study coordinator: Ian Chi Kei Wong, PhD
- Email: wongick@hku.hk
- Phone: +852 3917 9441
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clazakizumab for adults with high hsCRP at risk for a heart event
This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.
-
What personal, social, and access factors affect taking diabetes medicines
This project will see if patients' knowledge, beliefs, family support, healthcare communication, and access problems influence how adults with diabetes take their medicines.
-
Vicadrostat with empagliflozin for people with type 2 diabetes, high blood pressure, and heart disease
This trial will test whether adding vicadrostat to empagliflozin lowers cardiovascular risk in adults who have type 2 diabetes, high blood pressure, and existing cardiovascular disease but no history of heart failure.
-
Substituting high- with low-ultra-processed soy protein foods within a guideline-based diet for cardiometabolic health
This study tests whether a 12-week digital diet program with extra fruits and vegetables, combined with either low- or high-ultra-processed soy protein foods, can lower systolic blood pressure in adults with hypertension and obesity, about half of whom have type 2 diabetes.
-
Mobile app using daily incentives and action plans to build blood-pressure medication habits
This tests whether a smartphone app that gives daily incentives and/or action-planning prompts can help adults with hypertension who sometimes miss pills take their blood-pressure medication more regularly and control their blood pressure.
-
Evaluation of a pilot program for managing chronic diseases in Hong Kong
This study is testing a new program to see if it can help people aged 45 and older in Hong Kong manage their high blood pressure and diabetes better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.